Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Chromosome 15q Duplication (dup15q) Syndrome Clear all

Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

NCT05307679

View directory record Official record

Conditions: Dup15q Syndrome
Interventions: Basmisanil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 14 Years

Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Chicago, Illinois

Source: ClinicalTrials.gov public record

Updated Dec 11, 2025 · Synced May 21, 2026, 7:20 PM EDT

Completed Early Phase 1 Interventional

Angelman Syndrome (AS) Biomarker Study

NCT04103333

View directory record Official record

Conditions: Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
Interventions: Lumbar Puncture, Blood Collection; Procedure
Lead sponsor: Biogen; Industry
Eligibility: Up to 50 Years

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Source: ClinicalTrials.gov public record

Updated Jan 27, 2022 · Synced May 21, 2026, 7:20 PM EDT

Completed Phase 2 Interventional Results available

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

NCT03694275

View directory record Official record

Conditions: 15q Duplication Syndrome, CDKL5 Deficiency Disease
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 55 Years

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Norcross, Georgia + 3 more

Source: ClinicalTrials.gov public record

Updated May 25, 2022 · Synced May 21, 2026, 7:20 PM EDT